Top Metronidazole Brands: Trusted Names for Reliable Treatment

Metronidazole is a widely used antibiotic and antiprotozoal medication that is prescribed for various infections. Choosing a reliable brand is crucial to ensure effectiveness and safety. Several pharmaceutical companies offer metronidazole under different names, with variations in forms such as tablets, creams, and injections. Understanding the top brands can help you make an informed decision. To explore the best brands and their features, see the comprehensive list below.

Illustration of metronidazole

Best brands of metronidazole in 2025

Flagyl

Flagyl, a well-known brand of metronidazole, is recognized for its efficacy in treating parasitic and anaerobic bacterial infections. The global metronidazole market, which includes Flagyl, was estimated to be worth US$ 113 million in 2021 and is forecast to reach US$ 109.1 million by 2028, with a CAGR of -0.5% during the forecast period 2022-2030. Metronidazole, including Flagyl, is available in various forms such as tablets, capsules, and recently approved oral suspension, enhancing treatment compliance. The market is driven by increasing cases of infections and the need for effective treatments. Key players like Hongyuan Pharmaceutical and others are focusing on expanding their product portfolios.

Metrogyl

Metrogyl, a prominent brand of metronidazole, is recognized for its efficacy in treating a wide range of infections caused by bacteria and other organisms. Each Metrogyl tablet contains either 200 mg or 400 mg of metronidazole, and the drug is active against various pathogenic micro-organisms, including species of Bacteroides, Fusobacteria, and protozoa like Trichomonas and Giardia lamblia. Metrogyl is available in different formulations, including tablets and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The drug is rapidly absorbed, with peak plasma concentrations occurring within 20 minutes to 3 hours, and it is widely distributed into most body tissues and fluids. Metrogyl is a crucial component in the global metronidazole market, which is projected to grow at a CAGR of 5.1% from 2024 to 2031, reaching a market size of USD 139.97 million by 2031. For more detailed information, consult the resource document.

Noritate

Noritate, a brand of metronidazole cream, is renowned for its efficacy in treating inflammatory lesions and erythema of rosacea. Clinical studies have shown that Noritate reduces papules and pustules by 41-55% and erythema severity scores by 40-42% after 10 weeks of treatment. Each gram of Noritate cream contains 10 mg of micronized metronidazole, and it is applied once daily to the affected area. The cream has been evaluated in two randomized vehicle-controlled clinical studies involving 416 patients, demonstrating its safety and efficacy. With low systemic absorption, Noritate is a preferred topical treatment option. For more detailed information, please visit the DailyMed Noritate page.

Rosasol

Rosasol is a renowned brand that excels in producing metronidazole-based treatments, particularly for rosacea. Its cream formulation, containing 1% metronidazole, 7.5% octinoxate, and 2% avobenzone, has demonstrated significant reductions in inflammatory lesions, erythema, and telangiectasia in clinical studies. In a double-blind, randomized study, Rosasol cream showed a good to excellent response in 80% of patients compared to 20% in the placebo group over 12 weeks. The product also provides limited sun protection through its sunscreen components. Metronidazole in Rosasol has been proven to maintain remission of rosacea with a relapse rate of 23% in metronidazole-treated subjects over 6 months.

Metrogel

Metrogel, a brand of metronidazole, is renowned for its efficacy in treating inflammatory lesions of rosacea and other skin conditions. It is available in a 1% topical gel form, with each gram containing 10 mg of metronidazole, and is marketed by Galderma Laboratories. The product has a significant market presence, with the U.S. annual sales for metronidazole gel totaling approximately $62 million as of 2021. Topical administration of Metrogel results in minimal systemic absorption, with a mean Cmax of 32 ng/mL, which is less than 1% of the value reported for a single 250 mg oral dose of metronidazole. This makes Metrogel a preferred choice for targeted skin treatment. For more details, visit the Metrogel product page.

Vandazole

Vandazole, a brand of metronidazole vaginal gel, is a highly effective treatment for bacterial vaginosis in non-pregnant women, demonstrating a therapeutic cure rate of 42.8% in clinical trials. Each applicator full of Vandazole contains 37.5 mg of metronidazole, administered intravaginally once a day for 5 days. The gel exhibits low systemic absorption, with peak serum concentrations approximately 2% to 5% of those achieved with oral metronidazole. Vandazole is supplied in a 70 gram tube with 5 vaginal applicators and must be stored at controlled room temperature. Its safety and efficacy are well-documented, with common adverse reactions including fungal infection, headache, and pruritus.

Rozex

Rozex, a renowned brand, is highly regarded for its effective metronidazole formulations, particularly in treating rosacea. The Rozex Cream and Gel contain 0.75% metronidazole, which has been shown to significantly reduce inflammatory lesions of rosacea, with a median lesion count reduction of up to 61.3% over 12 weeks. Topical application of Rozex results in minimal systemic absorption, with the area under the curve (AUC) being only 1.2% of that from an oral 250mg dose. This localized action makes Rozex a safe and efficient treatment option. Clinical trials have demonstrated its efficacy in reducing rosacea symptoms, making it a preferred choice among dermatologists. For more detailed information, visit the Rozex product information page.

Nidagel

Nidagel, a brand of metronidazole vaginal gel, is a highly effective treatment for bacterial vaginosis, offering minimal serum levels of metronidazole compared to oral therapy, with a mean maximum serum concentration of approximately 2% of that achieved by oral administration. It is indicated for the treatment of bacterial infections in the vagina, particularly effective against anaerobic bacteria such as Bacteroides and Gardnerella vaginalis. The gel formulation ensures localized action, reducing systemic side effects. Bioavailability studies have shown that a single 5-gram dose results in a mean maximum serum concentration of 237 nanograms/ml, significantly lower than the 12,785 ng/ml from a 500 mg oral tablet. Nidagel is manufactured by Valeant Canada LP and has been a trusted treatment option since its revision in 2017. For more detailed information, you can refer to their official product document.

Promax

The global metronidazole market is dominated by several key players, including Hongyuan Pharmaceutical, Yinhe Aarti Pharmaceutical, Saikang Pharmaceutical, Zhongan Pharmaceutical, and Wuyao Pharmaceutical. These companies are known for their high-quality production and strategic market presence. For instance, the global metronidazole market size was estimated to be around $113 million in 2021 and is forecasted to reach $109.1 million by 2028, with a CAGR of -0.5% during the forecast period 2022-2030. The market growth is driven by increasing applications in both human and animal health sectors. Metronidazole is widely used in various forms, including tablets, capsules, and injections. For more detailed insights, refer to the Metronidazole Market Size, Growth, & Trends Report (2022-2030).

Metrocream

MetroCream, a product of Galderma Laboratories, is a leading brand for metronidazole topical cream, specifically formulated to treat inflammatory papules and pustules of rosacea. It contains 0.75% metronidazole and is applied twice daily to the affected areas. The cream is well-tolerated and has demonstrated significant improvements in reducing rosacea symptoms. Available in a 45g aluminum tube, MetroCream is stored at controlled room temperatures between 68°F to 77°F (20°C to 25°C). Its effectiveness has been established through various clinical trials, showing a total incidence of adverse reactions of approximately 10%.